Movatterモバイル変換

[0]ホーム
URL:

WO2003074004A3 - Method of producing antigens - Google Patents

Method of producing antigensDownload PDF

Info

Publication number
WO2003074004A3
WO2003074004A3PCT/US2003/006661US0306661WWO03074004A3WO 2003074004 A3WO2003074004 A3WO 2003074004A3US 0306661 WUS0306661 WUS 0306661WWO 03074004 A3WO03074004 A3WO 03074004A3
Authority
WO
WIPO (PCT)
Prior art keywords
producing
antigens
reactive
transglutaminase
cross
Prior art date
Application number
PCT/US2003/006661
Other languages
French (fr)
Other versions
WO2003074004A2 (en
Inventor
Szu-Yi Chou
Original Assignee
Szu-Yi Chou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/231,063external-prioritypatent/US20030224476A1/en
Priority claimed from US10/231,470external-prioritypatent/US7101695B2/en
Priority claimed from US10/231,298external-prioritypatent/US20030219853A1/en
Priority claimed from US10/231,114external-prioritypatent/US7485438B2/en
Priority claimed from US10/231,213external-prioritypatent/US20040001848A1/en
Application filed by Szu-Yi ChoufiledCriticalSzu-Yi Chou
Priority to AU2003213718ApriorityCriticalpatent/AU2003213718A1/en
Publication of WO2003074004A2publicationCriticalpatent/WO2003074004A2/en
Publication of WO2003074004A3publicationCriticalpatent/WO2003074004A3/en

Links

Classifications

Landscapes

Abstract

Embodiments of the invention generally provide methods and compositions for producing polyvalent antigens, disease-specific antigens, transglutaminase-reactive compounds, and recombinant transglutaminases. A method of producing a cross-linked compound by a biological agent is also provided. The invention provides a method for producing a cross-linked antigen and a method of using cross-linked products as antigens to immunize animals and induce strong immune responses. In addition, a method of producing an antigen specific for Alzheimer's disease is provided. Further, a method of producing a polyvalent antigen for two or more diseases is provided. Thus, compositions of antigens are prepared and provided to immunize animals and induce strong immune responses. The invention provides purified recombinant transglutaminases reactive to a broad range of compounds and exhibit broad substrate activity. Additionally, the invention provides a method of attaching one or more amino acid residues to a compound to be reactive with transglutaminase, even for transglutaminase non-reactive compounds.
PCT/US2003/0066612002-03-012003-03-03Method of producing antigensWO2003074004A2 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
AU2003213718AAU2003213718A1 (en)2002-03-012003-03-03Method of producing antigens

Applications Claiming Priority (14)

Application NumberPriority DateFiling DateTitle
US36116602P2002-03-012002-03-01
US60/361,1662002-03-01
US36344502P2002-03-082002-03-08
US60/363,4452002-03-08
US10/231,0632002-08-28
US10/231,063US20030224476A1 (en)2002-03-012002-08-28Method of producing transglutaminase reactive compound
US10/231,470US7101695B2 (en)2002-03-012002-08-28Method of producing transglutaminase having broad substrate activity
US10/231,2132002-08-28
US10/231,298US20030219853A1 (en)2002-03-012002-08-28Method of cross-linking a compound
US10/231,1142002-08-28
US10/231,114US7485438B2 (en)2002-03-012002-08-28Method of producing polyvalent antigens
US10/231,2982002-08-28
US10/231,4702002-08-28
US10/231,213US20040001848A1 (en)2002-03-012002-08-28Method of producing disease-specific antigens

Publications (2)

Publication NumberPublication Date
WO2003074004A2 WO2003074004A2 (en)2003-09-12
WO2003074004A3true WO2003074004A3 (en)2006-08-10

Family

ID=27792403

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/US2003/006661WO2003074004A2 (en)2002-03-012003-03-03Method of producing antigens

Country Status (2)

CountryLink
AU (1)AU2003213718A1 (en)
WO (1)WO2003074004A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8691224B2 (en)2005-11-302014-04-08Abbvie Inc.Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en)2006-11-302014-11-04Abbvie Inc.Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en)2007-02-272014-11-25AbbVie Deutschland GmbH & Co. KGMethod for the treatment of amyloidoses
US8961544B2 (en)2010-08-052015-02-24Lifebond Ltd.Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix
US8987419B2 (en)2010-04-152015-03-24AbbVie Deutschland GmbH & Co. KGAmyloid-beta binding proteins
US9017664B2 (en)2006-12-152015-04-28Lifebond Ltd.Gelatin-transglutaminase hemostatic dressings and sealants
US9176150B2 (en)2003-01-312015-11-03AbbVie Deutschland GmbH & Co. KGAmyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP2007522119A (en)*2004-01-282007-08-09キュリックス エーピーエス Conjugates of amyloid protein as vaccines for amyloid-related diseases
TW200726482A (en)*2005-06-302007-07-16Merck & Co IncMethod for preparing a covalently cross linked oligomer of amyloid beta peptides
KR20180058863A (en)2005-11-302018-06-01애브비 인코포레이티드Monoclonal antibodies against amyloid beta protein and uses thereof
EP2054435A1 (en)*2006-08-182009-05-06Novo Nordisk Health Care AGTransglutaminase variants with improved specificity
EP2118132A1 (en)*2007-02-222009-11-18Novo Nordisk Health Care AGTransglutaminase variants with improved specificity
EP2310459B1 (en)2008-06-182014-10-22Lifebond LtdImproved cross-linked compositions
EP2303341A2 (en)*2008-06-182011-04-06Lifebond LtdA method for enzymatic cross-linking of a protein
CA2782863A1 (en)2009-12-222011-06-30Lifebond LtdModification of enzymatic crosslinkers for controlling properties of crosslinked matrices
EP2603524A1 (en)2010-08-142013-06-19AbbVie Inc.Amyloid-beta binding proteins
US11998654B2 (en)2018-07-122024-06-04Bard Shannon LimitedSecuring implants and medical devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4544638A (en)*1984-05-181985-10-01The Regents Of The University Of CaliforniaSynthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en)*1994-09-292000-01-04Ajinomoto Co., Inc.Modification of peptide and protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4544638A (en)*1984-05-181985-10-01The Regents Of The University Of CaliforniaSynthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en)*1994-09-292000-01-04Ajinomoto Co., Inc.Modification of peptide and protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE JONG G.A.H. ET AL: "Purification and substrate specificity of transglutaminase from blood and Streptoverticillium mobaraense", JOUR. AGRIC FOOD CHEM., vol. 49, 2001, pages 3389 - 3393, XP003001875*
KAHLEM P. ET AL.: "Peptides containing glutamine repeats as substrates for transglutaminase catalyzed cross-linking: Relevance to diseases of the nervous system", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 14580 - 14585, XP000918974*

Cited By (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9176150B2 (en)2003-01-312015-11-03AbbVie Deutschland GmbH & Co. KGAmyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en)2005-11-302014-04-08Abbvie Inc.Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en)2005-11-302017-01-10AbbVie Deutschland GmbH & Co. KGAnti-Aβ globulomer 7C6 antibodies
US8877190B2 (en)2006-11-302014-11-04Abbvie Inc.Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en)2006-11-302016-06-07Abbvie Inc.Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en)2006-11-302016-07-19Abbvie Inc.Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9017664B2 (en)2006-12-152015-04-28Lifebond Ltd.Gelatin-transglutaminase hemostatic dressings and sealants
US8895004B2 (en)2007-02-272014-11-25AbbVie Deutschland GmbH & Co. KGMethod for the treatment of amyloidoses
US8987419B2 (en)2010-04-152015-03-24AbbVie Deutschland GmbH & Co. KGAmyloid-beta binding proteins
US8961544B2 (en)2010-08-052015-02-24Lifebond Ltd.Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix

Also Published As

Publication numberPublication date
WO2003074004A2 (en)2003-09-12
AU2003213718A1 (en)2003-09-16
AU2003213718A8 (en)2003-09-16

Similar Documents

PublicationPublication DateTitle
WO2003074004A3 (en)Method of producing antigens
WO2006031560A3 (en)Process for concentration of antibodies and therapeutic products thereof
WO2007002261A3 (en)IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
PL366826A1 (en)Reducing the immunogenicity of fusion proteins
CA2290485A1 (en)Method for the production of non-immunogenic proteins
WO2003017935A3 (en)Human antibodies specific for interleukin 15 (il-15)
WO2004043407A3 (en)Methods and products for treating staphylococcal infections
WO2000053758A3 (en)Compositions and methods for the treatment of immune related diseases
WO2005003296A3 (en)Albumin fusion proteins
MXPA05007211A (en)A pharmaceutical composition comprising an immunoglobulin fc region as a carrier.
EP2292664A3 (en)Multispecific deimmunized CD3-binders
WO2002043661A3 (en)Recombinant anti-cd30 antibodies and uses thereof
WO2002060955A3 (en)Modified antibodies and methods of use
AU2001294541A1 (en)Mammalian genes; related reagents and methods
WO2004065417A3 (en)Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2010044889A3 (en)Torque teno virus (ttv) isolates and compositions
ATE321859T1 (en) B2MICROGLOBULIN FUSION PROTEINS AND VARIANTS WITH HIGH AFFINITY
WO2012075173A3 (en)Compositions and method for deimmunization of proteins
WO2002012899A3 (en)Peptides presented by cells
AU4653301A (en)Anti-freeze proteins, their production and use
WO2005065711A3 (en)Mammalian receptor proteins; related reagents and methods
WO2002074921A3 (en)Methods for isolating proteins expressed by dendritic cells
WO2002044737A3 (en)Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor
WO2005121178A3 (en)Immunoaffinity chromatography polyol-responsive monoclonal antibodies
WO2000017363A3 (en)Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses

Legal Events

DateCodeTitleDescription
AKDesignated states

Kind code of ref document:A2

Designated state(s):AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

ALDesignated countries for regional patents

Kind code of ref document:A2

Designated state(s):GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121Ep: the epo has been informed by wipo that ep was designated in this application
122Ep: pct application non-entry in european phase
NENPNon-entry into the national phase

Ref country code:JP

WWWWipo information: withdrawn in national office

Country of ref document:JP
[8]ページ先頭
©2009-2025 Movatter.jp